SSY GROUP - VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for Cimetidine Injection (2ml: 0.2g) from National Medical Products

Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cimetidine Injection is mainly used for the treatment of digestive tract ulcer.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Acetylcysteine Solution for Inhalation (3ml: 0.3g) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Acetylcysteine Solution for Inhalation is mainly used for the treatment of respiratory diseases with excessive thick mucus secretions such as acute bronchitis, chronic bronchitis and its exacerbations, emphysema, viscous obstruction syndrome, and bronchiectasis. This product enhances the Group's nebulized expectorant product types, enriching their nebulized inhalation treatment options for respiratory diseases.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 30 July 2026